CDH6

Preliminary phase 2 results from the REJOICE-Ovarian01 trial show raludotatug deruxtecan (R-DXd) demonstrates clinically significant response in recurrent platinum-resistant ovarian, primary peritoneal, or fallopian tube cancer. The study observed a 50.5% objective response rate across all doses. The Phase 3 portion will evaluate a 5.6 mg/kg dose of R-DXd against chemotherapy. R-DXd, a CDH6-directed antibody drug conjugate, is being jointly developed by Daiichi Sankyo and Merck, highlighting collaborative efforts in oncology drug development due to high unmet needs in late stage ovarian cancer.